The mission of the Center for Cancer Research Development is to coalesce and foster outstanding, interactive, laboratory-based cancer research centered on the Molecular and Cellular Pathogenesis of Cancer. To this end, three program projects, each with two subprojects will be initiated in year one along with four pilot projects, the latter supported by funds from Rhode Island Hospital/Academic Medical Center (RIH/AMC). The goal will be to develop program projects in four different but related themes, into interactive research groups composed of at least 3 junior investigators supported by peer reviewed grants. This will be accomplished by establishing and perpetuating an intellectually dynamic training environment in which junior investigators will create and disseminate new knowledge and clinical applications and with the guidance of senior faculty mentors, build nationally competitive, independent, but interactive research programs. The investigators will utilize common model systems and state-of-the-art core facilities in administration, career development, proteomics and molecular pathology to 1) discover mechanisms leading to neoplasia and 2) develop clinical applications resulting from this knowledge. The six subprojects, mentored by a team of seven senior faculty including the PI and Co-PI, target programmatic themes in gastrointestinal cancer, developmental proteins and intracellular signaling pathways. A fourth theme in viral mechanisms of carcinogenesis is represented by pilot projects funded by the institution. The proposal represents a strategic partnership in which RIH/AMC will commit significant resources to supplement those requested in this application to build cohesive strength in basic cancer research that complements existing strengths in clinical cancer treatment, outreach, and prevention. The long-term goal of this support is to achieve NCI designation as a Comprehensive Cancer Center. Guidance for the Center will be provided by teams of Internal and External Advisors and Consultants including a Translational Research Group together with a carefully considered plan of training, evaluation and succession. The end result will be a Cancer Research Center of investigators with significant programmatic strengths and translational impact.

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
Exploratory Grants (P20)
Project #
1P20RR017695-01
Application #
6571754
Study Section
Special Emphasis Panel (ZRR1-RI-A (02))
Program Officer
Douthard, Regine
Project Start
2002-09-30
Project End
2007-08-31
Budget Start
2002-09-30
Budget End
2003-08-31
Support Year
1
Fiscal Year
2002
Total Cost
$1,554,248
Indirect Cost
Name
Rhode Island Hospital (Providence, RI)
Department
Type
DUNS #
161202122
City
Providence
State
RI
Country
United States
Zip Code
02903
Šrajer Gajdošik, Martina; Hixson, Douglas C; Brilliant, Kate E et al. (2018) Soft agar-based selection of spontaneously transformed rat prostate epithelial cells with highly tumorigenic characteristics. Exp Mol Pathol 105:89-97
Lopez, Chelsea E; Sheehan, Hannah C; Vierra, David A et al. (2017) Proteomic responses to elevated ocean temperature in ovaries of the ascidian Ciona intestinalis. Biol Open 6:943-955
Francois-Vaughan, Heather; Adebayo, Adeola O; Brilliant, Kate E et al. (2016) Persistent effect of mTOR inhibition on preneoplastic foci progression and gene expression in a rat model of hepatocellular carcinoma. Carcinogenesis 37:408-419
Li, Ming; Tucker, Lynne D; Asara, John M et al. (2016) Stem-loop binding protein is a multifaceted cellular regulator of HIV-1 replication. J Clin Invest 126:3117-29
Breen, Lucas D; Pu?i?-Bakovi?, Maja; Vu?kovi?, Frano et al. (2016) IgG and IgM glycosylation patterns in patients undergoing image-guided tumor ablation. Biochim Biophys Acta 1860:1786-94
Mulvey, Hillary E; Chang, Audrey; Adler, Jason et al. (2015) Extracellular vesicle-mediated phenotype switching in malignant and non-malignant colon cells. BMC Cancer 15:571
Cheng, Yan; Holloway, Michael P; Nguyen, Kevin et al. (2014) XPO1 (CRM1) inhibition represses STAT3 activation to drive a survivin-dependent oncogenic switch in triple-negative breast cancer. Mol Cancer Ther 13:675-86
Yousuf, Saad; Duan, MeiLi; Moen, Erika L et al. (2014) Raf kinase inhibitor protein (RKIP) blocks signal transducer and activator of transcription 3 (STAT3) activation in breast and prostate cancer. PLoS One 9:e92478
Panagopoulos, Kiriaki; Cross-Knorr, Sam; Dillard, Christen et al. (2013) Reversal of chemosensitivity and induction of cell malignancy of a non-malignant prostate cancer cell line upon extracellular vesicle exposure. Mol Cancer 12:118
Perez, K; Walsh, R; Brilliant, K et al. (2013) Heterogeneity of colorectal cancer (CRC) in reference to KRAS proto-oncogene utilizing WAVE technology. Exp Mol Pathol 95:74-82

Showing the most recent 10 out of 127 publications